United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent
October 07, 2024 10:00 ET
|
Liquidia Corporation
U.S. Supreme Court denied United Therapeutics’ petition to appeal rulings that found all claims of U.S. Patent No. 10,716,793 (‘793 Patent) were invalidDecisions that Liquidia does not infringe any...
Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)
October 02, 2024 06:00 ET
|
Liquidia Corporation
Liquidia and Pharmosa announced they have amended the current exclusive licensing agreement for the development and commercialization of L606.
Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting
September 30, 2024 08:00 ET
|
Liquidia Corporation
Liquidia will present a poster and host a medical theater at the CHEST 2024 annual meeting hosted by the American College of Chest Physicians this October.
Court Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million
September 16, 2024 09:41 ET
|
Liquidia Corporation
MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia), a biopharmaceutical company developing innovative therapies for patients with rare...
Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement
September 11, 2024 08:26 ET
|
Liquidia Corporation
Liquidia Corporation announces raise of $67.5M.
Liquidia to Present at Upcoming Investor Conferences
August 28, 2024 08:00 ET
|
Liquidia Corporation
Liquidia Corporation (LQDA) announced today that the company will present at two investor conferences this September.
Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA™ (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD
August 22, 2024 06:00 ET
|
Liquidia Corporation
Liquidia has filed litigation that challenges the recent decision by the FDA to grant 3-year new clinical investigation exclusivity to Tyvaso DPI.
U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
August 19, 2024 06:00 ET
|
Liquidia Corporation
The FDA has granted tentative approval of YUTREPIA™ (treprostinil) inhalation powder to treat adults with PAH and PH-ILD.
Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions
August 16, 2024 06:30 ET
|
Liquidia Corporation
Liquidia Corporation (NASDAQ: LQDA) will present nine encore thematic posters at the 2024 Pulmonary Hypertension Association (PHA) International Conference
Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 07, 2024 06:30 ET
|
Liquidia Corporation
Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the second quarter ended June 30, 2024.